Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00966875 · ClinicalTrials.gov registry record · Phase 2
A Study in Patients With Rheumatoid Arthritis
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 448
- Enrollment target
NCT00966875: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00966875 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 448 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00966875, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 448 participants
- Enrollment target
Study Summary
The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA): * The safety of LY2439821 and any side effects that might be associated with it. * Whether LY2439821 can help participants with active RA. * How much LY2439821 should be given to participants.
Primary Outcome
ACR20 responders are participants with at least 20% improvement from baseline for tender joint count (TJC), swollen joint count (SJC), and at least 3 of the 5 remaining core set measures: Health Assessment Questionnaire-Disability Index (HAQ-DI) which measured participants perceived degree of difficulty performing daily activities, C-reactive Protein (CRP), Patient's Assessment of Arthritis Pain-Visual Analog Scale (PAAP-VAS), Patient's Global Assessment of Disease Activity-VAS(PtGADA-VAS), and
Interventions
- DRUG Placebo
- BIOLOGICAL LY2439821
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 448 participants |
| Start Date | 2009-08 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
What the finished NCT00966875 record still lists
NCT00966875 is an interventional study that assigns participants to a tested intervention. The registered 448 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (237% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00966875 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00966875 about?
NCT00966875 is a clinical study titled "A Study in Patients With Rheumatoid Arthritis". The primary purpose of the study is to help answer the following research questions, and not to provide treatment for Rheumatoid Arthritis (RA): * The safety of LY2439821 and any side effects that might be associated with it. * Whether LY2439821 can help participants with active RA. * How much LY24...
What is the current status of trial NCT00966875?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 448 participants. The study started on 2009-08. Estimated completion is 2012-06.
What interventions are being tested in trial NCT00966875?
The interventions under investigation include: Placebo (DRUG), LY2439821 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00966875?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00966875's enrollment target sits among peer trials
448 89th of 2000 higher than 1,912 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06702449 · 448 participants · Phase 1
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- NCT07125053 · 448 participants · NA
COPD Resources, Education, and Activity Designed for You Study
- NCT04065399 · 447 participants · Phase 1
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia